AVEO is the first company able to identify genes responsible for tumor maintenance in addition to tumor growth. Its proprietary technology has enabled the company to create animal models that are far more representative of human cancer than conventional methods, to identify new drug targets, and to discover drug leads that are active against these targets. AVEO’s world class management team is led by proven entrepreneur and CEO, Tuan Ha-Ngoc, who established AVEO’s R&D collaboration with Merck which is worth up to $100M in fees and milestone payments. Flagship Ventures General Partner Doug Cole serves as Director.

www.aveopharma.com